Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Pancreatic cancer
Stage/Subtype:  stage III pancreatic cancer
Trial Type:  Treatment
Results 1-25 of 97 for your search:
Start Over
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: NLG0505, NCI-2013-01044, 1210-1195, NCT01836432
Surgery With or Without Intraperitoneal Drainage in Improving Complication Rate in Patients With Pancreatic Disease
Phase: Phase III
Type: Health services research, Treatment
Age: 18 and over
Trial IDs: H-28324, NCI-2012-01881, NCT01441492
Combination Chemotherapy with or without Stereotactic Body Radiation Therapy in Treating Patients with Locally Advanced Pancreatic Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 18
Trial IDs: PANC0015, NCI-2013-01658, 5136, NCT01926197
Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: INCB 18424-362, NCI-2014-01324, NCT02117479
A Study of Ruxolitinib in Pancreatic Cancer Patients
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: INCB 18424-363, NCI-2014-01487, NCT02119663
Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 85
Trial IDs: Neogenix 0901, NCI-2012-01393, NCT01040000
Gemcitabine Hydrochloride and Hydroxychloroquine Before Surgery in Treating Patients With High Risk Stage IIB-III Pancreatic Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 19 and over
Trial IDs: 09-122, NCI-2011-02492, NCT01128296
Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, and Erismodegib before Surgery in Treating Patients with Borderline Resectable Pancreatic Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J1130, NCI-2012-00064, CIR00003888, LDE225XUS03T, NA_00047491, NA_00047491 / CIR00004443, NCT01431794
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CMEK162X2109, NCI-2012-00874, 2011-002578-21, NCT01449058
A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCC 19211, NCI-2012-00026, NCT01506973
Genetically Engineered Lymphocytes in Treating Patients with Metastatic Cancer or Cancer That Cannot Be Removed by Surgery Receiving Chemotherapy and Aldesleukin
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 66
Trial IDs: 12-C-0111, NCI-2013-01516, 1112-1139, 120111, P11928, RD-12-I-02, NCT01583686
Safety Study of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: INCB 39110-116, NCI-2014-00116, NCT01858883
A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-032, NCI-2013-02337, 2013-002844-10, NCT01928394
PARP inhibitor BMN-673 in Treating Patients with Advanced Solid Tumors and BRCA Mutations
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-C-0015, NCI-2013-02371, 09-25-0099, 140015, P131220, P9510_A08PAMDREVW01, 9510, NCT01989546
Trametinib and Navitoclax in Treating Patients with Advanced or Metastatic Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-505, NCI-2014-00461, 9525, NCT02079740
Pembrolizumab and Combination Chemotherapy in Treating Patients with Advanced Colorectal, Gastroesophageal, Pancreatic, or Biliary Tract Cancer That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: HCI76239, NCI-2015-00123, 3475-085, 76239, MK-3475 GI, NCT02268825
Genetic Analysis-Guided Dosing of FOLFIRABAX in Treating Patients with Advanced Gastrointestinal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB14-0595, NCI-2014-02407, NCT02333188
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PCYC-1135-CA, NCI-2015-00591, NCT02403271
Neoadjuvant GMCI Plus mFOLFIRINOX and Chemoradiation for Non-Metastatic Pancreatic Adenocarcinoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 76
Trial IDs: PaTK02, NCI-2015-00859, NCT02446093
A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PB1201, NCI-2013-01411, NCT01834235
WEE1 Inhibitor MK-1775, Gemcitabine Hydrochloride, and Radiation Therapy in Treating Patients with Pancreatic Cancer That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UMCC 2013.094, NCI-2014-01214, HUM00079048, NCT01916551, NCT02037230
Lapatinib Ditosylate and Capecitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2008-437, NCI-2013-00670, NCT00881621
Gemcitabine Hydrochloride, Docetaxel, and Capecitabine in Treating Patients With Pancreatic Cancer Previously Treated With Surgery
Phase: Phase II
Type: Treatment
Age: 18 to 75
Trial IDs: AAAB4460, NCI-2011-00695, NCT00882310
Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic or Colorectal Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 0911010739, NCI-2010-01001, NCT01053013
Start Over